VivoSeq
Nephrology

Immunoglobulin a Nephropathy (igan)

4

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Immunoglobulin A Nephropathy (IgAN) is an early-stage landscape with 4 programs across 5 companies. The most active players are Novartis, ADARx Pharmaceuticals, Inc., Vor Biopharma. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2A

ADARx Pharmaceuticals, Inc.

1 program

Phase 2V

Vor Biopharma

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

Zigakibart

Novartis

ADX-038

ADARx Pharmaceuticals, Inc.

Telitacicept

Vor Biopharma

Phase 31

Felzartamab

Biogen

Approved
No programs

Analysis

Modality Breakdown

4programs
Small molecule250%
Monoclonal antibody125%
Protein / enzyme125%

Modality classified for 80% of 5 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting3 · 100%

Clinical Trials

Trial Activity

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)
Recruiting·Biogen logoBiogen·Phase 3·NCT06935357·454 enrolled
A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease
Recruiting·AADARx Pharmaceuticals, Inc.·Phase 2·NCT07522099·30 enrolled
An Open-label, Multicenter Study to Assess the Effect of Zigakibart Treatment on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adult Patients With IgA Nephropathy.
Recruiting·Novartis logoNovartis·Phase 2·NCT07146906·32 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)